Search
TC-2216
go.drugbank.com/drugs/DB06044InvestigationalTC-2216 is an investigational novel small molecule that is being developed as an oral treatment for depression and anxiety disorders.
Omburtamab
go.drugbank.com/drugs/DB15635Investigational[A191829] Omburtamab is under investigation in clinical trial NCT03275402 (131i-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/leptomeningeal Metastases). … [A242487, A242492] Omburtamab, formerly the murine anti-B7-H3 antibody 8H9, and its humanized forms are currently under clinical development for use in various cancers.
G17DT Immunogen
go.drugbank.com/drugs/DB04914InvestigationalIt is also in a phase II/III trial for advanced stomach cancer in combination with 5-fluorouracil and cisplatin and in a late phase II trial for advanced colorectal cancer in combination with irinotecan … It is in phase III trials for advanced pancreatic cancer as a monotherapy and in combination with gemcitabine.
Synonyms: G17DT (AN ANTIGASTRIN IMMUNOGEN)Pirlindole
go.drugbank.com/drugs/DB09244ExperimentalThis drug is classified as a reversible inhibitor of monoamine oxidase A enzyme (also known as a RIMA drug). It was developed and is currently used as an antidepressant in Russia. … The antidepressant efficacy and safety of pirlindole have been demonstrated in numerous studies and, supported by many years of clinical experience in the treatment of depression.
Metildigoxin
go.drugbank.com/drugs/DB13401InvestigationalCategories: Compounds used in a research, industrial, or household settingSodium apolate
go.drugbank.com/drugs/DB13477ExperimentalCategories: Compounds used in a research, industrial, or household settingBetadex
go.drugbank.com/drugs/DB03995InvestigationalCategories: Compounds used in a research, industrial, or household settingTandutinib
go.drugbank.com/drugs/DB05465InvestigationalTyrosine kinases are enzymes involved in several cellular processes and are known to be activated in cancer cells to drive tumor growth. … Phase I/II trials are underway.
Pozanicline
go.drugbank.com/drugs/DB05458InvestigationalIn radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR subtypes. … ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity